WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events WU-CART-007 demonstrated preliminary evidence of anti-leukemic
First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with R/R T-ALL/LBL Additional clinical data showcase the ability of WU-NK-101 to engage the adaptive immune system and suggest the potential for durable effectivenes.